Completed PHASE3 INTERVENTIONAL 2-arm NCT00117052

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism

Sponsor: Amgen

Conditions End Stage Renal Disease Secondary Hyperparathyroidism

Interventions cinacalcet

Updated 6 times since 2017 Last updated: May 21, 2013 Started: Sep 30, 2004 Primary completion: Nov 30, 2005 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on End Stage Renal Disease and Secondary Hyperparathyroidism, this trial is completed. The trial is conducted by Amgen and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.